T. Rowe Price Associates
DTIL icon

T. Rowe Price Associates’s Precision BioSciences DTIL Stock Holding History

T. Rowe Price Associates’s Portfolio DTIL Stock Details DTIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-19,900
Closed -$7.47M – 2952
2021
Q2 		$7.47M Sell
19,900
-1,056
-5% -$317K ﹤0.01% 1451
2021
Q1 		$6.51M Buy
+20,956
New +$7.34M ﹤0.01% 1439

Other funds holding DTIL

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

T. Rowe Price Associates's DTIL Position: Q3 2021 in Review

T. Rowe Price Associates sold out of Precision BioSciences (DTIL) in Q3 2021, closing a stake of 19,900 shares — an estimated $7.47M sold.

T. Rowe Price Associates first reported a position in DTIL in Q1 2021 and held it in 2 quarters. The position peaked at $7.47M in Q2 2021. 132 funds tracked by Wall St. Rank hold DTIL as of Q3 2021.

  • T. Rowe Price Associates reported no remaining Precision BioSciences position as of Q3 2021 after selling out during the quarter.
  • T. Rowe Price Associates sold 19,900 Precision BioSciences shares in Q3 2021, an estimated $7.47M.
  • T. Rowe Price Associates first reported a position in Precision BioSciences in Q1 2021 and held it in 2 quarters.
  • T. Rowe Price Associates's Precision BioSciences position peaked at $7.47M in Q2 2021.
  • 132 funds tracked by Wall St. Rank held Precision BioSciences as of Q3 2021.

Based on T. Rowe Price Associates's 13F filing for Q3 2021, filed 15 Nov 2021.